We jet off to Central London to meet Robin Carr, CEO of Myricx Bio, a startup developing antibody-drug conjugates (ADCs) to treat cancer.
The team’s idea – using a novel ADC payload inhibiting molecules called N-myristoyltransferases (NMTs) – helped them to bag an impressive £90M ($114M) Series A round in 2024.
Robin outlines Myricx’s journey from small molecule antivirals to the booming market of cancer ADCs, and how the transition from big pharma to biotech has been an energising experience for him.
--------------------This episode is sponsored by Kadans. Learn more about Kadans’ London Innovation Centre where life sciences companies grow from start-up to global player: https://bit.ly/kadans-myricxbio--------------------
⭐️ ABOUT THE SPEAKER
Robin kicked off his Myricx experience as chief development officer in November 2019, before rising to the CEO seat in August 2022. Before this, he was VP of drug discovery at Astex Therapeutics, before spending more than a decade in research executive roles at GSK. ending up as SVP Drug Design and Selection.
🔗 LINKS MENTIONED
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/robin-carr-myricx-bio-adc/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.
⏰ TIMESTAMPS
